Ann: Quarterly Activities Report - March 2016-EXG.AX, page-7

I agree with stellmac's sentiments.
Also, investors need to decide whether they trust management's comments in the "Gold Production Update" of 19th April that the lab assay procedural issue is a "teething problem" and that a "satisfactory resolution is imminent". Personally, I believe them.
Meanwhile, it appears to me that a highly emotional (dare I say irrational?) investor is taking an ultra-short-term view, and can't see the forest for the trees. Frankly, the register is better off without such individuals. The sooner savvy institutional investors cotton on to this story and take stock off the hands of emotional HNW investors, the better!
Perhaps a catalyst might be the announcement of resolution of the assaying issues, and the consequent banking of the second tranche payments? The share price then would certainly be worthy of a re-rating, IMO.
The fundamentals (along with the gold price) will ultimately determine the share price. And if secondary market investors don't take the share price higher, then the stock will be a sitting duck for corporate investors, with Zijin/Norton in the box seat. It would be a shame if a corporate took the company over for a song. A 40-50% premium on a sand-bagged share price would be extremely disappointing for regular investors who can envision the massive upside.
If I had my time over, I would have been watching the stock from the sidelines for years, & buying right now with my ears pinned back. Has "re-rating", "market darling" and "ASX 200 constituent" written all over it. Just need to get those assays / second tranche payments sorted, "imminently"
DYOR